Stryker Bringing in Big Money

SYK designs, manufactures, and markets many medical technologies, including implants and surgical equipment. With a market capitalization of nearly $149 billion and annual sales of nearly $22 billion (25% of it from overseas), Stryker is a leading player in the medical devices sector. It’s growing too, as it recently acquired a pain management solutions provider and an AI-based virtual care company.

As for its finances, SYK’s net sales increased 11.9% year-over-year to $5.5 billion. The company’s adjusted net earnings came in at $1.1 billion (up 17.3% year-over-year), while adjusted earnings per share grew 16.7% in a year, to $2.87. The consensus revenue estimate of $6.4 billion for the fiscal first quarter (ending December 2024) would be a 9.4% year-over-year increase, while the consensus per-share earnings estimate of $3.87 would be an 11.9% improvement in a year.

It’s no wonder SYK shares are up 18% this year – and they could rise more. MAPsignals data shows how Big Money investors are betting heavily on the forward picture of the stock.

Stryker Shares in Demand

Institutional volumes reveal plenty. Recently, SYK has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in SYK shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Stryker.

Stryker Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, SYK has had solid earnings growth and profits:

• 3-year earnings growth rate (+2.6%)
• Profit margin (+24%)

Source: FactSet

Plus, EPS is estimated to ramp higher this year by +12.1%.

Now it makes sense why the stock has been powering to new heights. SYK has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

Stryker has been a top-rated stock at MAPsignals. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Top 20 report multiple times in the last year. The blue bars below show when SYK was a top pick…rising with time:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Stryker Price Prediction

The SYK rally isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in SYK at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MAPsignals process here.